A5102716179- COVID-19 Clinical Research Studies
- SARS-CoV-2 and COVID-19 Research
- COVID-19 and healthcare impacts
- Food Allergy and Anaphylaxis Research
- Allergic Rhinitis and Sensitization
- Contact Dermatitis and Allergies
- Vaccine Coverage and Hesitancy
- COVID-19 and Mental Health
- COVID-19 diagnosis using AI
Ente Ospedaliero Ospedali Galliera
2021-2022
Heat-and-pepsin-sensitive plant food allergens (PR-10 and profilin) sometimes cause systemic reaction.To detect the risk factors for reactions induced by labile allergens.A retrospective multicenter study was performed on patients with a documented history of allergic reaction to age-matched controls oral allergy syndrome (OAS) same foods. Offending foods, their amount, state (solid or liquid), potential cofactors (nonsteroidal anti-inflammatory drugs, protonic pump inhibitors, exercise,...
Peanut allergy has not been well characterized in Italy.Our aim was to better define the clinical features of peanut Italy and detect proteins involved allergic reactions.A total 22 centers participated a prospective survey over 6-month period. Clinical histories were confirmed by vivo and/or vitro diagnostic means all cases. Potential risk factors for occurrence considered. Levels IgE Arachis hypogea (Ara h) 1, 2, 3, 6, 8, 9 profilin measured.A 395 patients (aged 2-80 years) enrolled. Of...
Cancer patients are exposed to a greater risk of COVID-19 infection, resulting in treatment delays and unnecessary hospitalizations. International authorities have suggested reducing visits hospitals guarantee continuity care. We developed home care project called Home Se-Cure (HSC) the oral, intramuscular, subcutaneous cancer therapy during COVID-19. The included living near Galliera Hospital. Patients received by registered nurses (RNs), whoperformed blood tests delivered therapies. were...
Background: mRNA-based vaccines have shown 95% protection from SARS-COV-2 disease in healthy populations. Initial findings cancer patients suggest a lower seroconversion and greater toxicity possibly related to myelo-immunosuppressive therapies.Methods: We conducted prospective study assess factors predicting poor adverse events following immunization (AEFI) the BNT162b2 vaccine on active treatment. The primary endpoint was (IgG<25 AU/mL) after 21 days second dose. Patients who ended...